Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits Price Target Forecast, Yielding 38.98% Profit

August 08, 2023
ELI LILLY AND COMPANY stock has achieved the forecasted price target set by QuantWave on April 26, 2023. The initial price at the time of the signal was 369.98 USD, with a predicted long direction. On August 8, 2023, the stock reached a price of 514.21 USD, resulting in a profit of 38.98% for investors who followed the forecast.

This success can be attributed to various factors contributing to the stock movement, such as positive earnings reports, successful product launches, and overall market trends in the pharmaceutical sector. QuantWave's accurate prediction showcases the platform's advanced analytics and effectiveness in guiding investors towards profitable opportunities.

QuantWave provides users with access to forecasting predictions for a wide range of stocks, offering potential for significant profits. For those interested in enhancing their investment strategies, QuantSchool offers comprehensive educational resources on how to utilize the QuantWave forecasting system effectively, providing key principles for generating consistent income in the financial markets.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....

LLYMarch 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation  ~2 min.

Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....

LLYMarch 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results  ~2 min.

Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....

LLYMarch 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry  ~1 min.

Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....

LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....

LLYMarch 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry?  ~2 min.

Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....

LLYMarch 14, 2025Eli Lilly and Company Reports Promising Results in Hair Regrowth Study  ~1 min.

Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....

LLYFebruary 28, 2025Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding 50 billion  ~1 min.

Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....

LLYFebruary 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development  ~1 min.

Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....

LLYFebruary 26, 2025ELI LILLY AND COMPANY Launches Additional Zepbound Vial Doses and Offers New Savings  ~2 min.

ELI LILLY AND COMPANY has recently announced the launch of additional Zepbound vial doses, as well as new savings for self-pay patients....

REGNAugust 15, 2024REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 18.25% Profit  ~1 min.

QuantWave's forecast for REGENERON PHARMACEUTICALS, INC. proved to be highly accurate, as the stock reached the predicted target price of 1172.09 $ on August 15, 2024, from the signal price of 991....

REGNAugust 19, 2024REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 14.57% Profit Margin  ~1 min.

On July 2nd, 2024, QuantWave issued a forecast signal for REGENERON PHARMACEUTICALS, INC., predicting a long position when the stock was trading at 1041.78 $....

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 16.89% Profit  ~1 min.

QuantWave's forecast for REGENERON PHARMACEUTICALS, INC. proved accurate as the stock reached the predicted target price on April 4, 2025....

VRTXJuly 30, 2024QuantWave Achieves 17.27% Profit Target for VERTEX PHARMACEUTICALS INCORPORATED  ~1 min.

QuantWave, the automated forecasting platform, has successfully hit its price target forecast for VERTEX PHARMACEUTICALS INCORPORATED, resulting in a profitable return of 17.27%....

REGNApril 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with a Profit of 17.63%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock successfully reached the price target forecasted by QuantWave on April 4, 2025. The forecast signal was given on February 4, 2025, at a price of 695....